Literature DB >> 28503124

Factor XIII Deficiency and Thrombocytopenia Are Frequent Modulators of Postoperative Clot Firmness in a Surgical Intensive Care Unit.

Sarah von Rappard1, Corina Hinnen2, Roger Lussmann3, Manuela Rechsteiner4, Wolfgang Korte4.   

Abstract

OBJECTIVE: Fibrinogen and factor XIII (FXIII) have been shown to critically influence clot firmness in the intraoperative setting and thus likely influence intraoperative bleeding. We were interested to identify potential modulators of postoperative clot firmness in a tertiary care hospital surgical intensive care unit setting, independent of their clinical course during surgery.
METHODS: 272 day-shift consecutive patients were evaluated for whole blood clot firmness evaluated by the ROTEM® EXTEM thrombelastometric assay and various potential modulators of clot firmness upon arrival at the surgical intensive care unit (SICU).
RESULTS: Maximum clot firmness on the SICU was found to be independently influenced by the amount of colloids given during surgery as well as by platelet count, fibrinogen concentration, and FXIII activity at the time of SICU admission. In patients with lowest clot firmness, FXIII activity was the most important independent modulator of clot firmness; in patients with the highest clot firmness, platelet count and fibrinogen concentration were the most important modulators of clot firmness. Deficiencies (i.e., results below normal range) of these modulators of clot firmness were most prevalent for FXIII (activity < 70%: 45% of cases), which was significantly more frequent than thrombocytopenia (<150 × 109/l: 32%) or fibrinogen deficiency (<1.5 g/l: 6%).
CONCLUSIONS: Postoperative clot firmness as evaluated by whole blood thrombelastometry (ROTEM EXTEM assay) is independently and frequently modulated though FXIII activity and the platelet count, while fibrinogen concentration is also an independent but much less frequent modulator. Different modulators show different influences, depending on the clot firmness being present. Colloids infused during surgery also independently modulate postoperative clot firmness. Based on our data, strategies can be developed to improving postoperative care of patients with bleedings or at risk for bleeding.

Entities:  

Keywords:  Clot firmness; Colloids; FXIII; Fibrinogen; ICU; Platelet count; Postoperative bleeding; Thrombeloastometry

Year:  2017        PMID: 28503124      PMCID: PMC5425767          DOI: 10.1159/000468946

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  70 in total

1.  Coagulation studies in preoperative neurosurgical patients.

Authors:  B Schramm; K Leslie; P S Myles; C J Hogan
Journal:  Anaesth Intensive Care       Date:  2001-08       Impact factor: 1.669

2.  Transfused stored platelets have the same haemostatic function as circulating native platelets.

Authors:  W W H Roeloffzen; H C Kluin-Nelemans; N J G M Veeger; L Bosman; J Th M de Wolf
Journal:  Vox Sang       Date:  2010-04-23       Impact factor: 2.144

3.  Preoperative coagulation screen does not predict intraoperative blood product requirements in orthotopic liver transplantation.

Authors:  D M Ritter; S R Rettke; R J Lunn; E J Bowie; D Ilstrup
Journal:  Transplant Proc       Date:  1989-06       Impact factor: 1.066

4.  Thromboelastometry-guided intraoperative haemostatic management reduces bleeding and red cell transfusion after paediatric cardiac surgery.

Authors:  Y Nakayama; Y Nakajima; K A Tanaka; D I Sessler; S Maeda; J Iida; S Ogawa; T Mizobe
Journal:  Br J Anaesth       Date:  2014-10-10       Impact factor: 9.166

5.  Thrombocytopenia in a surgical ICU.

Authors:  F Stéphan; J Hollande; O Richard; A Cheffi; M Maier-Redelsperger; A Flahault
Journal:  Chest       Date:  1999-05       Impact factor: 9.410

6.  Thromboelastography-guided transfusion decreases intraoperative blood transfusion during orthotopic liver transplantation: randomized clinical trial.

Authors:  S-C Wang; J-F Shieh; K-Y Chang; Y-C Chu; C-S Liu; C-C Loong; K-H Chan; S Mandell; M-Y Tsou
Journal:  Transplant Proc       Date:  2010-09       Impact factor: 1.066

7.  Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation.

Authors:  M W Mosesson; K R Siebenlist; I Hernandez; K N Lee; V J Christiansen; P A McKee
Journal:  J Thromb Haemost       Date:  2008-06-16       Impact factor: 5.824

8.  Postoperative fibrinogen level is associated with postoperative bleeding following cardiothoracic surgery and the effect of fibrinogen replacement therapy remains uncertain.

Authors:  L Yang; A Vuylsteke; C Gerrard; M Besser; T Baglin
Journal:  J Thromb Haemost       Date:  2013-08       Impact factor: 5.824

9.  Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery.

Authors:  Niels Rahe-Meyer; Cristina Solomon; Michael Winterhalter; Siegfried Piepenbrock; Kenichi Tanaka; Axel Haverich; Maximilian Pichlmaier
Journal:  J Thorac Cardiovasc Surg       Date:  2009-05-17       Impact factor: 5.209

10.  Intraoperative blood loss in pediatric liver transplantation: analysis of preoperative risk factors.

Authors:  Y M Ozier; B Le Cam; G Chatellier; D Eyraud; O Soubrane; D Houssin; C Conseiller
Journal:  Anesth Analg       Date:  1995-12       Impact factor: 5.108

View more
  2 in total

1.  The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition.

Authors:  Donat R Spahn; Bertil Bouillon; Vladimir Cerny; Jacques Duranteau; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Marc Maegele; Giuseppe Nardi; Louis Riddez; Charles-Marc Samama; Jean-Louis Vincent; Rolf Rossaint
Journal:  Crit Care       Date:  2019-03-27       Impact factor: 9.097

2.  Mild Acquired Factor XIII Deficiency and Clinical Relevance at the ICU-A Retrospective Analysis.

Authors:  Felix Carl Fabian Schmitt; Maik von der Forst; Wolfgang Miesbach; Sebastian Casu; Markus Alexander Weigand; Sonja Alesci
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.